LEO Pharma Presents New 12-Month Real-World Data for Tralokinumab at AAD 2026

The data shows sustained improvements in clinical outcomes for patients with moderate-to-severe atopic dermatitis.

Mar. 30, 2026 at 5:32pm

Got story updates? Submit your updates here. ›

LEO Pharma, a global leader in medical dermatology, presented new 12-month real-world data for its biologic treatment Tralokinumab at the American Academy of Dermatology (AAD) 2026 Annual Meeting. The data showed sustained improvements in clinical outcomes, including reduced disease severity and improved quality of life, for patients with moderate-to-severe atopic dermatitis.

Why it matters

The presentation of this real-world data is significant as it provides further evidence of Tralokinumab's long-term effectiveness in treating atopic dermatitis, a chronic and often debilitating skin condition. This data can help inform treatment decisions and give hope to patients struggling with this challenging disease.

The details

The real-world study followed 1,200 patients with moderate-to-severe atopic dermatitis who were treated with Tralokinumab for 12 months. The results showed that patients experienced a 57% reduction in disease severity, as measured by the Eczema Area and Severity Index (EASI) score, and a 45% improvement in quality of life, as assessed by the Dermatology Life Quality Index (DLQI).

  • The data was presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting on March 30, 2026.

The players

LEO Pharma

A global leader in medical dermatology that developed the biologic treatment Tralokinumab for atopic dermatitis.

Tralokinumab

A biologic treatment for moderate-to-severe atopic dermatitis developed by LEO Pharma.

American Academy of Dermatology (AAD)

A professional organization of dermatologists that hosts an annual meeting where new research and data are presented.

Got photos? Submit your photos here. ›

What they’re saying

“These real-world data demonstrate the long-term benefits of Tralokinumab in helping patients with moderate-to-severe atopic dermatitis achieve sustained improvements in their disease and quality of life.”

— Dr. Emma Guttman-Yassky, Professor and System Chair of Dermatology, Icahn School of Medicine at Mount Sinai

The takeaway

The presentation of this real-world data on Tralokinumab's long-term effectiveness is an important milestone that can help dermatologists and patients make more informed treatment decisions for managing moderate-to-severe atopic dermatitis, a chronic and often debilitating skin condition.